Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

Blood

Volumn 109, Issue 8, 2007, Pages 3214-3218

  Jabbour, Elias ^a   O'Brien, Susan ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a   Ferrajoli, Alessandra ^a   Ravandi, Farhad ^a   Cabanillas, Maria ^a   Thomas, Deborah A ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLINDNESS; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CAUDA EQUINA SYNDROME; CLINICAL ARTICLE; DEATH; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LIPOSOMAL DELIVERY; MALE; MENINGITIS; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; PAPILLEDEMA; PRIORITY JOURNAL; RISK ASSESSMENT; SEIZURE; SEPSIS; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34147108337     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-043646     Document Type: Article

References (17)

1. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005; 80:1517-1527.
2. Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985;12: 131-148.
3. Bleyer WA, Coccia PF, Sather HN, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol. 1983;1: 317-325.
4. Omura GA, Moffitt S, Vogler WR, Salter MM. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood. 1980;55:199-204.
5. Kantarjian HM, Walters RS, Smith TL, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988;72:1784-1789.
6. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
7. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091-2097.
8. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788-2801.
9. Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol. 1995;52:912-917.
10. Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11:2186-2193.
11. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110-3116.
12. Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol. 2007; 81:201-208.
13. Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004;22: 3916-3921.
14. Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104:1624-1630.
15. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580.
16. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394-3402.
17. McClune B, Buadi F, Aslam N, Przepiorka D. Intrathecal liposomal cytarabine (DepoCyt) is safe and effective for prevention of meningeal disease in patients with acute lymphoblastic leukemia and high-grade lymphoma treated with the hyper-CVAD regimen [abstract]. Blood. 2005;116:227b.